Sunder Mudaliar

ORCID: 0000-0002-1133-7771
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Diabetes Treatment and Management
  • Diabetes Management and Research
  • Metabolism, Diabetes, and Cancer
  • Pharmacology and Obesity Treatment
  • Pancreatic function and diabetes
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Diet and metabolism studies
  • Retinal Diseases and Treatments
  • Diabetes Management and Education
  • Genetic Associations and Epidemiology
  • Cancer Risks and Factors
  • Adipose Tissue and Metabolism
  • Cardiac Imaging and Diagnostics
  • Muscle metabolism and nutrition
  • Retinoids in leukemia and cellular processes
  • Chronic Kidney Disease and Diabetes
  • Heart Failure Treatment and Management
  • Schizophrenia research and treatment
  • Cardiovascular Function and Risk Factors
  • Retinal Imaging and Analysis
  • Parkinson's Disease Mechanisms and Treatments
  • Biochemical Acid Research Studies
  • Stroke Rehabilitation and Recovery
  • Chronic Disease Management Strategies
  • Apelin-related biomedical research

University of California, San Diego
2009-2024

University of Minnesota
2024

George Washington University
2024

University of Miami
2024

Geriatric Research Education and Clinical Center
2024

Milken Institute
2024

Medical University of South Carolina
2024

University of Iowa
2017-2024

University of Michigan–Ann Arbor
2024

Bruce W. Carter VA Medical Center
2024

Type 2 diabetes mellitus causes excessive morbidity and premature cardiovascular (CV) mortality. Although tight glycemic control improves microvascular complications, its effects on macrovascular complications are unclear. The recent publication of the EMPA-REG OUTCOME study documenting impressive benefits with empagliflozin (a sodium-glucose cotransporter [SGLT2] inhibitor) CV all-cause mortality hospitalization for heart failure without any classic atherothrombotic events is puzzling. More...

10.2337/dc16-0542 article EN Diabetes Care 2016-06-11

Metformin produced weight loss and delayed or prevented diabetes in the Diabetes Prevention Program (DPP). We examined its long-term safety tolerability along with loss, change waist circumference during DPP follow-up.The randomized double-blind clinical trial of metformin placebo followed by a 7-8-year open-label extension analysis adverse events, tolerability, effect adherence on circumference.No significant issues were identified. Gastrointestinal symptoms more common than participants...

10.2337/dc11-1299 article EN cc-by-nc-nd Diabetes Care 2012-03-13

OBJECTIVE Insulin adjustments to maintain glycemic control in individuals with type 1 diabetes often lead wide glucose fluctuations, hypoglycemia, and increased body weight. Dapagliflozin, an insulin-independent sodium–glucose cotransporter 2 (SGLT2) inhibitor, increases glucosuria reduces hyperglycemia diabetes. The primary objective of this study was assess short-term safety dapagliflozin combination insulin; secondary objectives included pharmacokinetic, pharmacodynamic, efficacy...

10.2337/dc13-2955 article EN Diabetes Care 2014-09-30

OBJECTIVE—Compare the efficacy, safety, and patient satisfaction of continuous subcutaneous insulin infusion (CSII) therapy with multiple daily injection (MDI) for patients type 2 diabetes. RESEARCH DESIGN AND METHODS—A total 132 CSII-naive diabetic were randomly assigned (1:1) to CSII (using aspart) or MDI (bolus aspart basal NPH insulin) in a multicenter, open-label, randomized, parallel-group, 24-week study. Efficacy was assessed HbA1c eight-point blood glucose (BG) profiles. Treatment...

10.2337/diacare.26.9.2598 article EN Diabetes Care 2003-09-01

OBJECTIVE—To assess the effects of adjunctive treatment with pramlintide, an analog β-cell hormone amylin, on 24-h glucose fluctuations and postprandial glucose, glucagon, triglyceride excursions in patients type 1 diabetes intensively treated continuous subcutaneous insulin infusion (CSII). RESEARCH DESIGN AND METHODS—In this study, 18 (16 whom could be evaluated) (age 44 ± 11 years, HbA1c 8.2 1.3% [mean SD]) were given mealtime injections 30 μg pramlintide t.i.d. for 4 weeks addition to...

10.2337/diacare.26.1.1 article EN Diabetes Care 2003-01-01

To determine whether glycogen synthase (GS) activity remains impaired in skeletal muscle of non-insulin-dependent diabetes mellitus (NIDDM) patients or can be normalized after prolonged culture, needle biopsies vastus lateralis were obtained from 8 healthy nondiabetic control (ND) and 11 NIDDM subjects. After 4-6 wk growth 4 d fusion media containing normal physiologic concentrations insulin (22 pM) glucose (5.5 mM), both basal (5.21 +/- 0.79 vs 9.01 1.25%, P < 0.05) acute insulin-stimulated...

10.1172/jci118906 article EN Journal of Clinical Investigation 1996-09-01

A primary human skeletal muscle culture (HSMC) system, which retains cellular integrity and insulin responsiveness for glucose transport was employed to evaluate regulation. As previously reported, cells cultured from non-insulin-dependent diabetic (NIDDM) subjects displayed significant reductions in both basal acute insulin-stimulated compared nondiabetic controls (NC). Fusion/differentiation of NC NIDDM HSMC elevated media (from 22 pM 30 microM) resulted increased activities but reduced...

10.1172/jci118352 article EN Journal of Clinical Investigation 1995-12-01

Diabetic subjects are at increased risk for developing coronary artery disease, in part because of oxidation LDL, which promotes atherogenesis. Troglitazone, a new antidiabetic drug the thiazolidinedione class, acts as an insulin sensitizer and improves hyperglycemia. Structurally, it contains tocopherol moiety similar to vitamin E has been shown have antioxidant properties vitro. Therefore, we evaluated whether troglitazone inhibited LDL both vitro type 2 diabetic ex vivo. Troglitazone...

10.2337/diabetes.48.4.783 article EN Diabetes 1999-04-01

Type 2 diabetes (T2DM) is a chronic metabolic disease and major public health burden worldwide. In 2021, per International Diabetes Federation statistics, approximately 537 million adults were living with diabetes.[1] This expected to increase 643 by 2030 staggering 783 2045. Unfortunately, 3 in 4 live low- middle-income countries. The hallmark of T2DM hyperglycemia due combination progressive impairment beta cell function worsening insulin resistance. Most patients are obese, obesity well...

10.4103/cdrp.cdrp_15_23 article EN cc-by-nc-sa Chronicle of Diabetes Research and Practice 2024-01-01

pressure was 7.75cmH 2 O, average use rate 55.7%, and time 151.3 minutes.There no difference of AHI (P = 0.527) CPAP 0.136) between before after suvorexant.Improvement were observed in 0.004) 4 hours above 0.001) suvorexant.A rise 90% suvorexant.Discussion: In our current study, by administering suvorexant to patients using with poor adherence, adherence improved exacerbation OSAS noticed.Hence, it is effective administer this suggests the possibility that can be used safely.

10.1111/jsr.34_12619 article EN Journal of Sleep Research 2017-10-01
Coming Soon ...